July 30 Webinar 3: Sharing and comparing feedback for the PMPRB Guidelines
•
0 likes•298 views
Webinar 3: Sharing and comparing feedback for the PMPRB Guidelines – July 30, 2020 at 12PM – 1PM EDT.
Recommended
Recommended
More Related Content
What's hot
What's hot (20)
Similar to July 30 Webinar 3: Sharing and comparing feedback for the PMPRB Guidelines
Similar to July 30 Webinar 3: Sharing and comparing feedback for the PMPRB Guidelines (20)
More from Canadian Organization for Rare Disorders
More from Canadian Organization for Rare Disorders (20)
Recently uploaded
Recently uploaded (20)
July 30 Webinar 3: Sharing and comparing feedback for the PMPRB Guidelines
- 1. Collaborating on Drug Pricing Guidelines for Cost-Effectiveness and Access Summer Webinar Series on the PMPRB Changes July 30, 2020 1
- 2. • Durhane Wong-Rieger, PhD, President & CEO, CORD • Mike Drummond, PhD, Professor Health Economics, Univ. of York, UK • Dr. Aneal Khan, Department of Medical Genetics, Univ. of Calgary • Ed Dybka, President & GM, Ipsen Biopharmaceuticals Canada • Rosalie Wyonch, Policy Analyst, C.D. Howe Institute • Fred Horne, Policy Analyst, former Alberta Minister of Health MODERATOR Bill Dempster, 3Sixty Public Affairs Today’s roundtable 2
- 3. JULY 16 Federal Price Controls and Access to Medicines Webinar Series JUNE 25 JULY 30 Has the PMPRB removed the obstacles to access in its Guidelines? at noon at noon at noon Hearing From Those Who Matter Collaborating on Drug Pricing Guidelines for Cost- Effectiveness and Access
- 4. • The capping arguments: • Take the country changes which would bring you to the middle of the OECD countries – that already is the starting point • We have a process that gets developers and payers together to land on a price – not the best but not the worst – and the PMPRB will make that worse • Canada can do better – alternatives exist globally – we just need to have a more open mind to the options – we’re on the cusp of huge opportunities for rare diseases strategies and funding, but the PMPRB PREPARING TO PROVIDE INPUT TO PMPRB 4 LET’S HELP THE FEDERAL GOVERNMENT GET IT RIGHT
- 5. Recap and Update on Changes in PMPRB Federal Regulations • Changes on How PMPRB Sets Prices: - NEW: List of comparator countries to set Maximum List Price: Drop 2 highest and add 5 lower priced countries - NEW: Regulated Maximum Rebated Price (MRP) unilaterally set by PMPRB using new economic factors - NEW: Arbitrary, uniquely Canadian MRP cap set using cost/QALY and therapeutic class levels determined by staff New list (PMPRB11) FRANCE UK GERMANY ITALY SWEDEN AUSTRALIA BELGIUM JAPAN NORWAY NETHERLANDS SPAIN USA SWITZERLAND
- 6. Moving Canada to the lower end of OECD 3.21 1.06 1.00 0.97 0.94 0.94 0.92 0.89 0.88 0.86 0.85 0.84 0.83 0.83 0.81 0.81 0.80 0.80 0.79 0.79 0.78 0.76 0.74 0.72 0.71 0.70 0.69 0.69 0.67 0.67 0.54 0.34 USASw itzerland Canada Germ any New Zealand M exico Japan Chile Austria Sw eden Italy Finland UK Ireland OECD M EDIAN* Hungary SpainNetherlands BelgiumLuxem bourg Norw ay France Australia Portugal Slovakia Czech Republic Poland Greece Estonia SloveniaSouth Korea Turkey Average Foreign-to-Canadian Price Ratios, Patented Medicines, OECD, 2017 Calculated at medicine level for medicines with prices available in at least three foreign markers Source: From Figure 21 of the PMPRB Annual Report 2017; MIDASTM database, 2017, IQVIA. 40-70% Current comparator New comparator Canadian regulated public prices drop by ~20% and potentially further based on therapeutic class comparison (TCC) test Further reductions of net (confidential) prices bring total regulated reductions to as much as 50% off median international price (MIP) PMPRB 11 median = 0.80
- 7. Drug Development Health Canada Review ($) Patented Medicine Prices Review Board Health Technology Assessment ($) Hospitals Patient Access Public Drug Plans PMPRB new process Private Drug Plans NoC + 12-24+ months to access Challenging predictability
- 8. 8